Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis

DNA and Cell Biology

Volumn 32, Issue 4, 2013, Pages 188-198

  Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; NONALCOHOLIC FATTY LIVER; PPAR GAMMA 2 GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; FATTY LIVER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; PPAR GAMMA; RISK FACTORS;

EID: 84876135427     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2012.1947     Document Type: Article

References (40)

1. Amarapurkar, D.N., Hashimoto, E., Lesmana, L.A., Sollano, J.D., Chen, P.J., and Goh, K.L. (2007). How common is nonalcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 22, 788-793.
2. Bego, T., Dujic, T., Mlinar, B., Semiz, S., Malenica, M., Prnjavorac, B., Ostanek, B., Marc, J., and Causevic, A. (2011). Association of PPARG and LPIN1 gene polymorphisms with metabolic syndrome and type 2 diabetes. Med Glas (Zenica) 8, 76-83.
3. Bhatt, S.P., Nigam, P., Misra, A., Guleria, R., Luthra, K., Pandey, R.M., and Pasha, M.A. (2013). Association of peroxisome proliferator activated receptor-gamma gene with nonalcoholic fatty liver disease in Asian Indians residing in north India. Gene 512, 143-147.
4. Cao, C.Y., Li, Y.Y., Zhou, Y.J., Nie, Y.Q., and Wan, Y.J. (2012). The C-681G polymorphism of the PPAR-gamma gene is associated with susceptibility to non-alcoholic fatty liver disease. Tohoku J Exp Med 227, 253-262.
5. Clark, J.M., Brancati, F.L., and Diehl, A.M. (2002). Nonalcoholic fatty liver disease. Gastroenterology 122, 1649-1657.
6. Daly, A.K., Ballestri, S., Carulli, L., Loria, P., and Day, C.P. (2011). Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 5, 253-263.
7. Day, C.P., and James, O.F. (1998). Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 842-845.
8. Deeb, S.S., Fajas, L., Nemoto, M., Pihlajamaki, J., Mykkanen, L., Kuusisto, J., Laakso, M., Fujimoto, W., and Auwerx, J. (1998). A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20, 284-287.
9. Delahanty, L.M., Pan, Q., Jablonski, K.A., Watson, K.E., McCaffery, J.M., Shuldiner, A., Kahn, S.E., Knowler, W.C., Florez, J.C., and Franks, P.W. (2012). Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care 35, 363-366.
10. Dongiovanni, P., Rametta, R., Fracanzani, A.L., Benedan, L., Borroni, V., Maggioni, P., Maggioni, M., Fargion, S., and Valenti, L. (2010). Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol 10, 102.
11. Dongxia, L., Qi, H., Lisong, L., and Jincheng, G. (2008). Association of peroxisome proliferator-activated receptorgamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ J 72, 551-557.
12. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A.M., Saladin, R., Najib, J., Laville, M., Fruchart, J.C., Deeb, S., Vidal-Puig, A., Flier, J., Briggs, M.R., Staels, B., Vidal, H., and Auwerx, J. (1997). The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272, 18779-18789.
13. Farrell, G.C., and Larter, C.Z. (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112.
14. Gawrieh, S., Marion, M.C., Komorowski, R., Wallace, J., Charlton, M., Kissebah, A., Langefeld, C.D., and Olivier, M. (2012). Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci 57, 952-957.
15. Gonzalez Sanchez, J.L., Serrano Rios, M., Fernandez Perez, C., Laakso, M., and Martinez Larrad, M.T. (2002). Effect of the Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 147, 495-501.
16. Gupta, A.C., Chaudhory, A.K., Sukriti, Pande, C., Sakhuja, P., Singh, Y., Basir, S.F., and Sarin, S.K. (2010). Peroxisome proliferators-activated receptor gamma2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatol Int 5, 575-580.
17. Gurnell, M. (2005). Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function: lessons from human genetic studies. Best Pract Res Clin Endocrinol Metab 19, 501-523.
18. Hernaez, R. (2012). Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 35, 32-41.
19. Ho, J.S., Germer, S., Tam, C.H., So, W.Y., Martin, M., Ma, R.C., Chan, J.C., and Ng, M.C. (2012). Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res Clin Pract 97, 483-491.
20. Hui, Y., Yu-Yuan, L., Yu-Qiang, N., Wei-Hong, S., Yan-Lei, D., Xiao-Bo, L., and Yong-Jian, Z. (2008). Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int 28, 385-392.
21. Kallwitz, E.R., McLachlan, A., and Cotler, S.J. (2008). Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 14, 22-28.
22. Kotronen, A., Yki-Jarvinen, H., Aminoff, A., Bergholm, R., Pietilainen, K.H., Westerbacka, J., Talmud, P.J., Humphries, S.E., Hamsten, A., Isomaa, B., Groop, L., Orho-Melander, M., Ehrenborg, E., and Fisher, R.M. (2009). Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur J Endocrinol 160, 593-602.
23. Masud, S., and Ye, S. (2003). Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 40, 773-780.
24. Masugi, J., Tamori, Y., Mori, H., Koike, T., and Kasuga, M. (2000). Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptorgamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268, 178-182.
25. Mohanty, S.R., Troy, T.N., Huo, D., O'Brien, B.L., Jensen, D.M., and Hart, J. (2009). Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 50, 797-804.
26. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ 339, b2535.
27. Morris, D.R., Moxon, J.V., Biros, E., Krishna, S.M., and Golledge, J. (2012). Meta-analysis of the association between transform-ing growth factor-beta polymorphisms and complications of coronary heart disease. PLoS One 7, e37878.
28. Ochoa, M.C., Marti, A., Azcona, C., Chueca, M., Oyarzabal, M., Pelach, R., Patino, A., Moreno-Aliaga, M.J., Martinez-Gonzalez, M.A., and Martinez, J.A. (2004). Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord 28 Suppl 3, S37-S41.
29. Passaro, A., Dalla Nora, E., Marcello, C., Di Vece, F., Morieri, M.L., Sanz, J.M., Bosi, C., Fellin, R., and Zuliani, G. (2011). PPARgamma Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome. Cardiovasc Diabetol 10, 112.
30. Qureshi, K., and Abrams, G.A. (2007). Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 13, 3540-3553.
31. Rajeevan, H., Osier, M.V., Cheung, K.H., Deng, H., Druskin, L., Heinzen, R., Kidd, J.R., Stein, S., Pakstis, A.J., Tosches,N.P., Yeh, C.C., Miller, P.L., and Kidd, K.K. (2003). ALFRED-the ALlele FREquency Database-update. Nucleic Acids Res 31, 270-271.
32. Rey, J.W., Noetel, A., Hardt, A., Canbay, A., Alakus, H., Zur Hausen, A., Dienes, H.P., Drebber, U., and Odenthal, M. (2010). Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma2 in patients with fatty liver diseases. World J Gastroenterol 16, 5830-5837.
33. Ruhl, C.E., and Everhart, J.E. (2004). Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 8, 501-519, vii.
34. Scheen, A.J. (2001). Thiazolidinediones and liver toxicity. Diabetes Metab 27, 305-313.
35. Tellechea, M.L., Aranguren, F., Perez, M.S., Cerrone, G.E., Frechtel, G.D., and Taverna, M.J. (2009). Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor-gamma gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men: interaction with smoking status. Circ J 73, 2118-2124.
36. Thakkinstian, A., McEvoy, M., Minelli, C., Gibson, P., Hancox, B., Duffy, D., Thompson, J., Hall, I., Kaufman, J., Leung, T.F., Helms, P.J., Hakonarson, H., Halpi, E., Navon, R., and Attia, J. (2005) Systematic review and metaanalysis of the association between b2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162, 201-211.
37. Tsochatzis, E.A., Manolakopoulos, S., Papatheodoridis, G.V., and Archimandritis, A.J. (2009). Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol 44, 6-14.
38. Williams, R. (2006). Global challenges in liver disease. Hepatology 44, 521-526.
39. Yang, Z., Wen, J., Li, Q., Tao, X., Ye, Z., He, M., Zhang, W., Huang, Y., Chen, L., Ling, C., Qu, S., and Hu, R. (2012). PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Mol Cell Endocrinol 348, 255-259.
40. Zhou, Y.J., Li, Y.Y., Nie, Y.Q., Yang, H., Zhan, Q., Huang, J., Shi, S.L., Lai, X.B., and Huang, H.L. (2010). Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol 25, 772-777.